For ER+ breast cancers, neoadjuvant endocrine therapy other than chemotherapy might be a more appropriate choice for Luminal-A LABCs; however, there is a lack of consensus on the threshold indication for inclusion of NCT for the Luminal-B subtype. The gene discussed is ESR1; the disease is breast carcinoma.